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Abstract
Methionine aminopeptidase 2 (MetAP2) is a bifunctional protein that plays a critical role in the
regulation of post-translational processing and protein synthesis. MetAP2 is overexpressed in
human colon cancer. In this report we screened various MetAP2 inhibitors and treated HT29 cells
with various concentrations of compounds. We evaluated the expression of MetAP2 and pp60c-src
expressions in HT29 cells. In addition we also carried out the cell proliferation and cell cycle
analysis in the MetAP2 inhibitor-treated HT29 cells. The cell cycle analysis of HT29 treated with
1.0 μM of NC2213 showed an arrest in the G2 phase followed by an induction in the percentage
of cells undergoing apoptosis in the sub-G1 phase. Western blot analysis revealed that the MetAP2
expression was dose-dependently decreased when the HT29 cells were treated with the 3,5-
bis(benzylidene)-4-piperidone derivative (NC2213). In addition, phosphorylation of Src, a
myristoylated oncoprotein was significantly decreased by 1.0 μM of NC2213 as revealed by
Western blot analysis. Furthermore, NC2213 also inhibits the expression of pp60c-src in HT29 cells.
Interestingly, this compound also inhibits the phosphorylation at Tyr416 of pp60c-src  while
increasing the phosphorylation at Tyr527 of pp60c-src. NC2213 inhibits the growth of HT29 cells
by inducing apoptosis and might be useful for the treatment of human colon cancer.
Findings
Methionine aminopeptidases (MetAPs) are the enzymes
responsible for the removal of methionine from the
amino-terminus of newly synthesized proteins [1,2]
which is essential for further amino terminal modifica-
tions (e.g., myristoylation of glycine by N-myristoyltrans-
ferase, NMT) [3,4]. Various reports suggested that MetAP2
plays an important role in the growth of different types of
tumors [5]. Anti-sense of MetAP2 also induces apoptosis
in rat hepatoma cells [6]. A recent study suggested that
fumagillin effectively inhibits both liver tumor growth
and metastasis in rats in vivo [7]. Higher MetAP2 expres-
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sion was reported in malignant mesothelioma [8], malig-
nant lymphomas [9] and esophageal squamous
carcinomas [10]. The angiogenesis inhibitor TNP470, O-
(chloro-acetyl-carbamoyl) fumagillol, a synthetic ana-
logue of fumagillin, suppressed the expression of MetAP2
in human neuroblastoma and thus, MetAP2 may be an
important molecular target for human neuroblastomas
[11]. Earlier, we demonstrated the high expression of
MetAP2 in colorectal adenocarcinoma patients [12]. It
appears that higher expression of MetAP2 is required for
the overexpression of NMT in colon carcinogenesis.
The purpose of the present study is to identify a novel
MetAP2 inhibitor. We screened various small molecules
using a cell proliferation (MTT) assay. Among several
compounds screened, we identified 2-{3-[3,5-bis[4-
nitrobenzylidene]-4-oxopiperidin-1-yl]-3-oxopropylsul-
fanyl} ethanesulfonic acid NC2213 (Figure 1), which is
structurally divergent from fumagillin, as an inhibitor of
MetAP2. Various cytotoxic evaluations against human
squamous cells (HSC-2, HSC-4), and leukemic cells (HL-
60) displayed moderate inhibition [13]. HT29 colon can-
cer cells were treated with NC2213 at a concentration
range of 0 to 5.0 μM for 96 hours to confirm a dose-
dependent inhibitory effect. NC2213 inhibited HT29
cells, human colon cancer cell lines (HCCL), in a dose-
dependent manner with an IC50 value of 1.2 μM (Figure
2A). HT29 cell proliferation was significantly inhibited by
1.0 μM of NC2213. The effects of NC2213 on cell cycle
progression and cell death in HT29 cells were analyzed by
flow cytometric analysis of the DNA content using fixed,
propidium iodide-stained cells. HT29 cells were exposed
to NC2213 at various concentrations for 48 hours. The
addition of NC2213 (1.0 μM) seemed to abrogate the G2-
M arrest and significantly increased the population of cells
with sub-G (apoptotic) DNA content. The percentage of
G1 cells decreased 50% with 1.0 μM NC2213 after 48
hours. The cell cycle analysis of HT29 treated with 1.0 μM
of NC2213 showed an arrest in the G2 phase followed by
an induction in the percentage of cells undergoing apop-
tosis in the sub-G1 phase (Figure 2B).
To investigate the inhibition of MetAP2 by NC2213, the
dose-dependent effects of NC2213 were evaluated by
Western blot analysis. HT29 cells, treated with NC2213
for 48 hours, led to a dramatic decrease in MetAP2 expres-
sion (Figure 3A). Very recently, it has been reported that
MetAP2 could function as an oncogene [14]. An adenovi-
rus transfer of cMyc increased the expression of MetAP2 in
human umbilical vein endothelial cells revealed that cel-
lular proliferation may involve a cross-talk between cMyc
and MetAP2. Furthermore, various Src family tyrosine
kinases, ADP ribosylation factors and eukaryotic tran-
scription elongation factor-2 were substrates of MetAP2
which plays a significant role in the progression of metas-
tasis [14]. From our above observations it is evident that
MetAP2 may serve as a novel target for the treatment of
colon cancer. MetAP2 is one such target candidate due to
its inactivation by the widely investigated anticancer agent
TNP470 [15-17]. A derivative of the natural product fum-
agillin, TNP470 has been shown to be safe and effective in
the treatment of solid tumors in several animal studies
and preclinical trials. TNP470 entered human clinical tri-
als for the treatment of AIDS-related Kaposi's sarcoma,
metastatic breast cancer, androgen-independent prostate
cancer, pediatric solid tumors, lymphomas, acute leuke-
mia, advanced squamous cell cancer of the cervix, and
metastatic renal carcinoma [18-20]. Several MetAP2
inhibitors were studied based on the inhibition of MetAP
activity [21-27]. Previously, inhibition of MetAP2 by
TNP470 has been shown to activate p53 for cell-cycle
arrest [25,26]. In fact, the primary mouse embryonic
fibroblasts were demonstrated to be sensitive to TNP470
and other MetAP2-specific inhibitors in a p53-dependent
fashion [25,26]. In contrast, the majority of transformed
tumor cells are largely resistant to TNP470, likely due to
the pre-existing p53 mutations in them.
c-Src is frequently observed to be activated or overex-
pressed in a number of human cancers, especially those of
colon and breast. Activation of c-Src is achieved upon its
myristoylation for proper signal transduction. Since myr-
istoylation reaction is catalyzed by NMT, we reported that
a cross-talk among the MetAP2, NMT, and N-myristoyl-
transferase inhibitor protein 71 (NIP71) in HT29 cells
[27]. Importantly, the Src family kinases have been shown
to play pivotal roles in cell-cycle progression, making
them potential candidates to mediate the cell-cycle effects
of MetAP inhibitors. Western blot analysis revealed that
phosphorylation of Src was significantly decreased by 1.0
μM of NC2213 (Figure 3B). We further investigated the
molecular events associated with NC2213-induced cell
cycle arrest by measuring the phosphorylation of Src, a
myristoylated protein, is elevated in human colon cancer
(Figure 3B). The phosphorylation of Src at Tyr417 and
Tyr527 in HT29 cells was measured by Western blot anal-
ysis (Figure 3B). These observations lead us to the possi-
Structure of NC2213 Figure 1
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A, cell proliferation analysis of HT29 cells Figure 2
A, cell proliferation analysis of HT29 cells. The cells were treated with NC2213 or DMSO (control) at various concen-
trations for 96 hours; B, cell cycle analysis of HT29 cells. The cells were treated with NC2213 or DMSO (control) at various 
concentrations for 48 hours. Histograms represent the PI staining of DNA content in different phases of the cell cycle. Per-
centages of cells in each phase of the cell cycle are shown on the histograms. The data presented as the representative of at 
least three separate experiments.Molecular Cancer 2009, 8:65 http://www.molecular-cancer.com/content/8/1/65
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bility of developing MetAP2 specific inhibitors, which
may be therapeutically useful. In addition, it is important
to study the regulation of MetAP2 and its involvement of
various signal transduction pathways.
The possible role of MetAP2 and NMT in cell proliferation
may be due to the interaction of these enzymes with vari-
ous apoptotic factors. Increased expression of NMT in p53
mutant cases suggests that wild-type p53 may have a neg-
ative regulatory effect on NMT gene expression [28].
MetAP2 plays a critical role in the proliferation of
endothelial cells and certain tumor cells and thus serves as
a promising target for anti-angiogenesis and anticancer
drugs [10]. It has been demonstrated that there is a high
expression of MetAP2 in human mesothelioma tissue,
and the association of this expression with anti-apoptotic
function in those neoplastic cells [8]. In addition, the
inhibition of MetAP2 expression in mesothelioma cells
leads to cell death and that such apoptosis is avoided in
cases where there is overexpression of Bcl-2 [8]. The
upregulation of Bcl-2 in colorectal cancer is well estab-
lished by various investigators [28-30]. One of the other
mechanisms correlating with MetAP2 and apoptosis is
through caspases [8]. A recent observation suggested that
mesalazine-induced apoptosis in colon cancer cells is pos-
sible through activation of caspase-3 [31]. Chen et al
reported a reduction in protein levels of caspase-3, cas-
pase-7, and caspase-9 in human colon cancer specimens
[32].
In summary, we have identified a novel MetAP2 inhibitor
NC2213, which is a structurally divergent to fumagillin, in
HT29 cells. The MetAP2 expression was dose-dependently
decreased when the HT29 cells were treated with NC2213.
NC2213 also inhibits the expression of pp60c-src and the
phosphorylation at Tyr417 while increasing the phospho-
rylation at Tyr527 of pp60c-src  in HT29 cells. Future
detailed studies related to MetAP2 and apoptosis will shed




Anti-MetAP2 was purchased from Zymed Laboratories
Inc., (USA). Anti-pp60c-src, anti-phospho-Src (Tyr527],
and anti-phospho-Src (Tyr416] were purchased from Cell
Signaling, USA. Cell culture media, anti-β-Actin and other
reagents were from Invitrogen and Sigma. NC2213 was
synthesized as described earlier (Figure 1) [13].
Cell Culture and Cell Lysate Preparation
The HT29 cells were grown as described elsewhere [27].
Cell Proliferation Assay
Cells were dissociated with 2.5 g/L trypsin and resus-
pended in tissue culture media. Cells (1 × 105 cells/mL)
were added to 96-well plates (9000 cells/well) for 24 h at
37°C. NC2213 was added at various concentrations rang-
ing from 05 μM. After the cells were incubated with
NC2213 for 96 h, cell proliferation was estimated based
on the cellular reduction of tetrazolium salt MTT by using
a micro plate reader (BIO-RAD, Model 550 USA) at 540
nm [33].
Cell Cycle Analysis
Cell cycle analysis was carried out as described elsewhere
[34]. Cells were treated with NC2213 at various concen-
trations ranging from 05 μM. After treatment for 48 h,
cells were trypsinized, washed in PBS, and fixed overnight
in 70% ethanol at 4°C. At the time of harvest, the cultures
were 7090% confluent. The ethanol solution was subse-
quently removed after centrifugation, and cells were resus-
Expression of MetAP2 and Src in HT29 cells Figure 3
Expression of MetAP2 and Src in HT29 cells. A, 
expression of MetAP2; B, expression of Src. Cells were 
treated with NC2213 at various concentrations for 48 hours. 
Equal amounts of proteins were loaded on to each lane, sub-
jected to SDS-PAGE, transferred to nitrocellulose mem-
brane, and blotted with anti-MetAP2, anti-pp60c-src, anti-
phospho-Src (Tyr527), anti-phospho-Src (Tyr416), as 
described under Materials and Methods. β-Actin was used as 
a loading control. The data presented as the representative 
of at least three separate experiments.Molecular Cancer 2009, 8:65 http://www.molecular-cancer.com/content/8/1/65
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pended in a buffer containing 10 mM Tris (pH 7.5), 125
mM sucrose, 2.5 mM MgCl2, 0.185% NP40, 0.02 mg/ml
RNase A, 0.05% sodium citrate, and 25 μg/ml PI. After
incubation on ice for 1 h, cells were subjected to DNA
content analysis using a FACScan cytometer (Becton Dick-
inson).
SDS-Polyacrylamide Gel Electrophoresis and Western Blot 
Analysis
SDS-PAGE prepared according to the procedure described
by Laemmli[35]. Gel transfer to nitrocellulose membrane
and blocking were performed using standard procedures
[36]. The blot was incubated with the primary antibodies
at 1:1000, washed and probed with an anti-rabbit or anti-
mouse IgG horseradish peroxidase conjugate diluted
1:2000.
Other Methods
Protein concentration was measured by the method of
Bradford [37] using bovine serum albumin as a standard.
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